Chargement en cours...
4CPS-099 Nivolumab: clinical experience in a tertiary hospital
BACKGROUND: Nivolumab is a human immunoglobulin G4 monoclonal antibody, which binds to the programmed death-1 receptor and blocks its interaction with PD-L1 and PD-L2. It is approved for melanoma, renal, urhotelial, non-small cell lung cancer (NSCLC) and other types of cancer. PURPOSE: To evaluate t...
Enregistré dans:
| Publié dans: | Eur J Hosp Pharm |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Group
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535528/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.190 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|